OCX (OncoCyte Corp.) סך נכסי החברה
OncoCyte Corporation (OCX) is developing molecular diagnostics for the early detection of oncology, creating sustainable demand and a predictable cash flow. The price visualization assisting in the basic asset valuation reflects the dynamics of total assets, which currently stand at 65.73. The business relies on DetermaRx test sales, yet faces a rigorous struggle for insurance reimbursement and pressure from resource-heavy market players.
פילוחים אנליטיים ודוחות נתונים של חברת OncoCyte Corp. (OCX)
Total assets determine the issuer's aggregate resource potential, where this assessment of controlled resources, calculated inversely through return on assets (ROA), demonstrates the dynamics of capital accumulation. For OncoCyte Corporation (OCX), this indicator reflects the value of the specialized infrastructure required to comply with strict FDA regulations when handling biomaterials, allowing the investor to differentiate the company's actual tangible asset base from the speculative value of the shares.